First MNC Drug Retailer To Enter China Restructures Operation
This article was originally published in PharmAsia News
Executive Summary
Medicine Shoppe, the first MNC drug retailer to enter China five years ago, is restructuring in response to difficulty in developing the market. It is closing down its eastern branch, and will be focusing on the country's eastern and southern regions this year. The company has adopted a franchise model to accelerate its market entry but faces shortcomings amidst intense competition. Medicine Shoppe plans to step up brand marketing and raise standards for new franchisees. It will now concentrate on penetrating deeper into the market it currently operates in rather than expanding into new cities. (Click here for more - Chinese Language
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.